Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMIBUW5)

Drug Name
GW-788388 Drug Info
Synonyms
452342-67-5; GW788388; 4-(4-(3-(pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydro-2H-pyran-4-yl)benzamide; GW-788388; GW 788388; UNII-N14114957J; CHEMBL202887; N14114957J; 4-[4-[3-(Pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl]-N-(tetrahydropyran-4-yl)benzamide; N-(oxan-4-yl)-4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}benzamide; 4-(4-(3-(Pyridin-2-yl)-1H-pyrazol-4-yl)pyridin-2-yl)-N-(tetrahydropyran-4-yl)benzamide; cc-69; SCHEMBL373524; SCHEMBL17926774; CTK8C0589; DTXSID70196444; EX-A122; AOB2606
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Investigative [1]
Cross-matching ID
PubChem CID
10202642
ChEBI ID
CHEMBL202887
CAS Number
CAS 452342-67-5
TTD Drug ID
DMIBUW5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Preclinical Drug(s)
Discontinued Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting LCK tyrosine protein kinase (LCK)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [4]
VX-680 DM93YKJ Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
JNJ-26483327 DMSQ3AZ Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
ISIS-CRP DMQDUG4 Cardiovascular disease BA00-BE2Z Phase 1 [6]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [7]
Bisindolylmaleimide-I DMOQJZC Discovery agent N.A. Investigative [7]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole DMN9YOB Discovery agent N.A. Investigative [8]
CI-1040 DMF3DZX Discovery agent N.A. Investigative [7]
AMP-PNP DMTOK1D Discovery agent N.A. Investigative [9]
BMS-536924 DMXJB4N Discovery agent N.A. Investigative [10]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting TGF-beta receptor type I (TGFBR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LY2157299 DMP8HW1 Arteriosclerosis BD40 Phase 2/3 [11]
TEW-7197 DM2LBC3 Myeloproliferative neoplasm 2A20 Phase 2 [12]
Metelimumab DMENFD6 Scleroderma 4A42 Phase 1/2 [13]
TP-0184 DMJVZBC Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
P-2745 DMJ3PNS Chronic myelogenous leukaemia 2A20.0 Phase 1 [15]
LY3200882 DMQP6VB Solid tumour/cancer 2A00-2F9Z Phase 1 [16]
PF-06952229 DMDQJEZ Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
SB-431542 DM0YOXQ Pulmonary fibrosis CB03.4 Preclinical [18]
SM-16 DMHXJV2 Fibrosis GA14-GC01 Terminated [19]
LF-984 DMIYMS2 Fibrosis GA14-GC01 Terminated [20]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ozagrel DMIGKA1 Xerophthalmia 5B55.Y Phase 4 [21]
Losmapimod DMIL37Z Acute coronary syndrome BA41 Phase 3 [21]
VX-702 DMKJDR6 Coronary artery disease BA80 Phase 2a [22]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [23]
Dilmapimod DMBYJ92 Acute lung injury NB32.3 Phase 2 [21]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [24]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [24]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [24]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [24]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Plasminogen activator inhibitor 1 (SERPINE1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [25]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [26]
Spironolactone DM2AQ5N Chronic heart failure BD1Z Approved [27]
Methotrexate DM2TEOL Anterior urethra cancer Approved [28]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [29]
Quercetin DM3NC4M Obesity 5B81 Approved [30]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [31]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [32]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [33]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [34]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [35]
2-deoxyglucose DMIAHVU Solid tumour/cancer 2A00-2F9Z Approved [36]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [37]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [38]
Ofloxacin DM0VQN3 Acute gonococcal cervicitis Approved [39]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [40]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [39]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [41]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [42]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [43]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Glutathione S-transferase Mu 2 (GSTM2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [44]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [45]
Testosterone DM7HUNW Hot flushes GA30 Approved [46]
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [46]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [47]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [48]
Eicosapentaenoic acid/docosa-hexaenoic acid DMMUCG4 Hypertriglyceridemia 5C80.1 Approved [49]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [50]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [51]
Arsenic DMTL2Y1 N. A. N. A. Approved [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By 1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Calcitriol DM8ZVJ7 Congenital alopecia LC30 Approved [53]
Calcidiol DMN4CV5 Hypophosphatemia Approved [54]
Calcipotriol DM03CP7 Psoriasis EA90 Approved [55]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [56]
Quercetin DM3NC4M Obesity 5B81 Approved [57]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [58]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [59]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [60]
Liothyronine DM6IR3P Congenital hypothyroidism Approved [61]
Testosterone DM7HUNW Hot flushes GA30 Approved [46]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Mothers against decapentaplegic homolog 2 (SMAD2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [62]
Quercetin DM3NC4M Obesity 5B81 Approved [63]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [64]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [65]
Panobinostat DM58WKG Chronic graft versus host disease Approved [66]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [67]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [68]
Sevoflurane DMC9O43 Anaesthesia 9A78.6 Approved [68]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [69]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [47]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Transcription factor MafF (MAFF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [70]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [71]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [72]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [73]
Quercetin DM3NC4M Obesity 5B81 Approved [57]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [31]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [74]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [75]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [76]
Nefazodone DM4ZS8M Major depressive disorder 6A70.3 Approved [33]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
LCK tyrosine protein kinase (LCK) TT860QF LCK_HUMAN Inhibitor [1]
Stress-activated protein kinase 2a (p38 alpha) TTQBR95 MK14_HUMAN Inhibitor [1]
TGF-beta receptor type I (TGFBR1) TTP4520 TGFR1_HUMAN Inhibitor [1]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrial (CYP24A1) OTG2T749 CP24A_HUMAN Gene/Protein Processing [2]
Glutathione S-transferase Mu 2 (GSTM2) OTG4WT05 GSTM2_HUMAN Gene/Protein Processing [2]
Mothers against decapentaplegic homolog 2 (SMAD2) OTC6VB4K SMAD2_HUMAN Gene/Protein Processing [3]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Gene/Protein Processing [2]
Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1) OTA675TJ GTR1_HUMAN Gene/Protein Processing [2]
Transcription factor MafF (MAFF) OT9B7MX0 MAFF_HUMAN Gene/Protein Processing [2]
Wilms tumor protein OTP7KC3D WT1_HUMAN Gene/Protein Processing [2]

References

1 Discovery of 4-{4-[3-(pyridin-2-yl)-1H-pyrazol-4-yl]pyridin-2-yl}-N-(tetrahydro-2H- pyran-4-yl)benzamide (GW788388): a potent, selective, and orall... J Med Chem. 2006 Apr 6;49(7):2210-21.
2 Capturing time-dependent activation of genes and stress-response pathways using transcriptomics in iPSC-derived renal proximal tubule cells. Cell Biol Toxicol. 2023 Aug;39(4):1773-1793. doi: 10.1007/s10565-022-09783-5. Epub 2022 Dec 31.
3 T-2 toxin induces articular cartilage damage by increasing the expression of MMP-13 via the TGF- receptor pathway. Hum Exp Toxicol. 2022 Jan-Dec;41:9603271221075555. doi: 10.1177/09603271221075555.
4 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
5 National Cancer Institute Drug Dictionary (drug id 596693).
6 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
7 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
8 Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
9 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
10 Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
11 Cardiac Safety of TGF-beta Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study. Cardiovasc Toxicol. 2015 Oct;15(4):309-23.
12 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
13 Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov. 2004 Dec;3(12):1011-22.
14 Clinical pipeline report, company report or official report of Sumitomo Dainippon Pharma.
15 Novel potent inhibitor of Bcr-Abl mutated imatinib resistant chronic myeloid leukemia cell lines. Cancer Research. 06/2012; 72(8 Supplement):1822-1822.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 Targeting the TGF pathway for cancer therapy. Pharmacol Ther. 2015 Mar;147:22-31.
18 Pyrazolone based TGFbetaR1 kinase inhibitors. Bioorg Med Chem Lett. 2010 Jan 1;20(1):326-9.
19 TGF-beta type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol. 2007 Feb;19(2):117-26.
20 US patent application no. 2013,0028,978, Compositions and methods for wound treatment.
21 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
22 Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
23 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
24 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
25 Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. Pharm Res. 2010 Oct;27(10):2162-74. doi: 10.1007/s11095-010-0219-2. Epub 2010 Jul 29.
26 Unique signatures of stress-induced senescent human astrocytes. Exp Neurol. 2020 Dec;334:113466. doi: 10.1016/j.expneurol.2020.113466. Epub 2020 Sep 17.
27 Effect of spironolactone on impaired fibrinolysis of hypertensive patients. Kidney Blood Press Res. 2002;25(4):260-4. doi: 10.1159/000066348.
28 Association of cell cycle arrest with anticancer drug-induced epithelial-mesenchymal transition in alveolar epithelial cells. Toxicology. 2019 Aug 1;424:152231. doi: 10.1016/j.tox.2019.06.002. Epub 2019 Jun 4.
29 Simvastatin inhibits tissue factor and plasminogen activator inhibitor-1 secretion by peripheral blood mononuclear cells in patients with primary nephrotic syndrome. Eur J Med Res. 2007 May 29;12(5):216-21.
30 Polyphenols downregulate PAI-1 gene expression in cultured human coronary artery endothelial cells: molecular contributor to cardiovascular protection. Thromb Res. 2007;121(1):59-65. doi: 10.1016/j.thromres.2007.02.001. Epub 2007 Mar 26.
31 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
32 Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes. Diabetologia. 2000 Mar;43(3):377-83. doi: 10.1007/s001250050057.
33 Robustness testing and optimization of an adverse outcome pathway on cholestatic liver injury. Arch Toxicol. 2020 Apr;94(4):1151-1172. doi: 10.1007/s00204-020-02691-9. Epub 2020 Mar 10.
34 Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep. 2008 Sep;35(3):421-9.
35 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
36 Insulin regulation of hexose transport in mouse 3T3-L1 cells expressing the human HepG2 glucose transporter. J Biol Chem. 1990 Nov 25;265(33):20106-16.
37 Effects of troglitazone on cellular differentiation, insulin signaling, and glucose metabolism in cultured human skeletal muscle cells. Biochem Biophys Res Commun. 2001 Jan 26;280(3):664-74. doi: 10.1006/bbrc.2000.4216.
38 Cannabidiol Displays Proteomic Similarities to Antipsychotics in Cuprizone-Exposed Human Oligodendrocytic Cell Line MO3.13. Front Mol Neurosci. 2021 May 28;14:673144. doi: 10.3389/fnmol.2021.673144. eCollection 2021.
39 Disturbance of cellular glucose transport by two prevalently used fluoroquinolone antibiotics ciprofloxacin and levofloxacin involves glucose transporter type 1. Toxicol Lett. 2009 Jan 30;184(2):81-4. doi: 10.1016/j.toxlet.2008.10.017. Epub 2008 Oct 28.
40 Minimal peroxide exposure of neuronal cells induces multifaceted adaptive responses. PLoS One. 2010 Dec 17;5(12):e14352. doi: 10.1371/journal.pone.0014352.
41 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
42 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
43 Essential role of cell cycle regulatory genes p21 and p27 expression in inhibition of breast cancer cells by arsenic trioxide. Med Oncol. 2011 Dec;28(4):1225-54.
44 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
45 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
46 Effects of 1alpha,25 dihydroxyvitamin D3 and testosterone on miRNA and mRNA expression in LNCaP cells. Mol Cancer. 2011 May 18;10:58.
47 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
48 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
49 Astaxanthin and omega-3 fatty acids individually and in combination protect against oxidative stress via the Nrf2-ARE pathway. Food Chem Toxicol. 2013 Dec;62:869-75.
50 Simulation of interindividual differences in inactivation of reactive para-benzoquinone imine metabolites of diclofenac by glutathione S-transferases in human liver cytosol. Toxicol Lett. 2016 Jul 25;255:52-62.
51 Expression of glutathione S-transferase M2 in stage I/II non-small cell lung cancer and alleviation of DNA damage exposure to benzo[a]pyrene. Toxicol Lett. 2010 Feb 15;192(3):316-23. doi: 10.1016/j.toxlet.2009.11.003. Epub 2009 Nov 10.
52 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
53 DNA microarray analysis of vitamin D-induced gene expression in a human colon carcinoma cell line. Physiol Genomics. 2004 Apr 13;17(2):122-9. doi: 10.1152/physiolgenomics.00002.2003.
54 Retinoic acid via RARalpha inhibits the expression of 24-hydroxylase in human prostate stromal cells. Biochem Biophys Res Commun. 2005 Dec 30;338(4):1973-81. doi: 10.1016/j.bbrc.2005.10.178. Epub 2005 Nov 7.
55 Actions of Vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology. 1995 Jan;136(1):20-6.
56 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
57 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
58 Effect of retinoic acid on gene expression in human conjunctival epithelium: secretory phospholipase A2 mediates retinoic acid induction of MUC16. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4050-61.
59 Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest. 2005 Jan;115(1):177-86.
60 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res. 2005 Mar 15;65(6):2488-97.
61 Similarities and differences between two modes of antagonism of the thyroid hormone receptor. ACS Chem Biol. 2011 Oct 21;6(10):1096-106.
62 MS4A3-HSP27 target pathway reveals potential for haematopoietic disorder treatment in alimentary toxic aleukia. Cell Biol Toxicol. 2023 Feb;39(1):201-216. doi: 10.1007/s10565-021-09639-4. Epub 2021 Sep 28.
63 Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: implications for the treatment of excessive scars. J Trauma. 2004 Nov;57(5):1032-7. doi: 10.1097/01.ta.0000114087.46566.eb.
64 Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
65 Glucosamine promotes osteogenic differentiation of dental pulp stem cells through modulating the level of the transforming growth factor-beta type I receptor. J Cell Physiol. 2010 Oct;225(1):140-51.
66 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
67 Endoplasmic reticulum stress contributes to arsenic trioxide-induced intrinsic apoptosis in human umbilical and bone marrow mesenchymal stem cells. Environ Toxicol. 2016 Mar;31(3):314-28.
68 The differential cancer growth associated with anaesthetics in a cancer xenograft model of mice: mechanisms and implications of postoperative cancer recurrence. Cell Biol Toxicol. 2023 Aug;39(4):1561-1575. doi: 10.1007/s10565-022-09747-9. Epub 2022 Aug 12.
69 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
70 Cannabidiol induces antioxidant pathways in keratinocytes by targeting BACH1. Redox Biol. 2020 Jan;28:101321. doi: 10.1016/j.redox.2019.101321. Epub 2019 Sep 5.
71 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
72 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
73 A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol. 2010 Sep;29(3):171-92.
74 Effects of ciglitazone and troglitazone on the proliferation of human stomach cancer cells. World J Gastroenterol. 2009 Jan 21;15(3):310-20.
75 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
76 Temporal changes in gene expression in the skin of patients treated with isotretinoin provide insight into its mechanism of action. Dermatoendocrinol. 2009 May;1(3):177-87.